Moderate to severe negative symptoms predict low risk of symptoms worsening in schizophrenia patients in CATIE
Schizophrenia Research · 2026-09 · 295 · 150-155
DOI: 10.1016/j.schres.2026.06.004 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Schizophrenia Research, 2026-09. Verfasst von Helene Speyer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Grigore T. Popa University of Medicine and Pharmacy, Iași, Romania; Mental Health Services in the Capital Region of Denmark, Denmark. Hauptthemen laut MEDLINE: Schizophrenia, Antipsychotic Agents, Disease Progression. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Understanding predictors of schizophrenia course is critical for long-term clinical management, yet prior findings have been inconsistent due to small samples, infrequent assessments, and non-standardized measures. Using data from phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), which includes a large cohort with monthly standardized evaluations, this study investigated whether baseline negative symptom severity predicts risk of symptom exacerbation over time. Participants were 1139 adults aged 18-65 years meeting DSM-IV criteria for schizophrenia. Symptoms worsening or exacerbation was defined as a ≥12-point increase from baseline on the PANSS total score. Cox regression survival models examined the association between baseline PANSS negative symptom tertiles and time to exacerbation, adjusting for age, sex, years since first prescribed antipsychotic medication, randomized antipsychotic treatment group, PANSS positive and general psychopathology subscales, and CGI-Severity. Overall, 25.5% of participants experienced exacerbation over an 18-month period of follow-up. Survival curves demonstrated significant separation across negative symptom tertiles (p < 0.05), with higher baseline negative symptoms associated with longer time to exacerbation. Compared with the lowest tertile, medium and high negative symptom groups showed reduced exacerbation risk (HR = 0.72 and HR = 0.70, respectively; both p < 0.04). Findings indicate that greater baseline negative symptom severity is associated with a lower likelihood of short-term symptom worsening, suggesting a relatively stable illness course among individuals with more severe negative symptoms. These results have implications for prognosis and treatment planning, while underscoring the persistent functional burden imposed by negative symptoms despite lower exacerbation risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Grigore T. Popa University of Medicine and Pharmacy, Iași, Romania; Mental Health Services in the Capital Region of Denmark, Denmark.
- Bar-Ilan University, Israel. Electronic address: Jonathan.Rabinowitz@biu.ac.il.
- Minerva Neurosciences, USA.
- Grigore T. Popa University of Medicine and Pharmacy, Iași, Romania.
Zitieren
APA
Speyer, H., Rabinowitz, J., Luthringer, R., Tamba, B. I., & Davidson, M. (2026). Moderate to severe negative symptoms predict low risk of symptoms worsening in schizophrenia patients in CATIE. Schizophrenia Research, 295, 150-155. https://doi.org/10.1016/j.schres.2026.06.004
Vancouver
Speyer H, Rabinowitz J, Luthringer R, Tamba BI, Davidson M. Moderate to severe negative symptoms predict low risk of symptoms worsening in schizophrenia patients in CATIE. Schizophrenia Research. 2026;295:150-155. doi:10.1016/j.schres.2026.06.004
BibTeX
@article{Speyer2026,
author = {Speyer, Helene and Rabinowitz, Jonathan and Luthringer, Remy and Tamba, Bogdan Ionel and Davidson, Michael},
title = {Moderate to severe negative symptoms predict low risk of symptoms worsening in schizophrenia patients in CATIE},
journal = {Schizophrenia Research},
year = {2026},
volume = {295},
pages = {150--155},
doi = {10.1016/j.schres.2026.06.004}
}
EUVIMED